The HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation, and mutation, or by MET or HGF protein overexpression.     ///    "This review summarizes the key biological features of the HGF-MET axis, its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are in development. "    ///    The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment..     ///    Targeting the dysregulated HGF-MET pathway is an area of active research. 